公开(公告)号：WO2019241466A1

公开(公告)日：2019-12-19

申请号：PCT/US2019/036892

申请日：2019-06-13

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： BERGESON, Susan, E. ,  SYAPIN, Peter ,  REID, Ted, W.

IPC: A61K31/65 ,  C07C237/26 ,  A61P25/32 ,  A61P25/36 ,  A61P31/00

Abstract: A method of treating Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: providing a subject with an effective amount of a modified tetracycline or derivative thereof to ameliorate or eliminate the AUD, SUD, tobacco use, pain, or proinflammatory disorder, and wherein the modified tetracycline or derivative thereof has reduced binding to a microbial ribosome and has the formula wherein R1 is acetyl, R2 is OH or acetyl, R3 is acetyl, R4 is H or acetyl, and R5 is acetyl.

公开(公告)号：WO2022240936A1

公开(公告)日：2022-11-17

申请号：PCT/US2022/028695

申请日：2022-05-11

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： REID, Ted, W. ,  FRALICK, Joe ,  TRAN, Phat, L. ,  BERFELD, Nicholas ,  SUNDIN, Olof

IPC: G01N33/553 ,  A61K31/095 ,  A61K33/04 ,  A61K33/08 ,  A61K33/24 ,  A61K47/50

Abstract: The present invention includes composition and methods for making and using a selenium-carrier conjugate for in vivo administration comprising: covalently attaching a selenium compound that reacts in vivo with naturally occurring reduced thiols and oxygen to produce superoxide, which can include a Fenton Complex that allows for a generation of hydroxyl radicals, and that wherein the selenium-carrier conjugate is stabilized against enzymatic degradation and clearance from the body and the synthetic targeting carrier binds target.

公开(公告)号：WO2019241490A1

公开(公告)日：2019-12-19

申请号：PCT/US2019/036928

申请日：2019-06-13

Applicant: TEXAS TECH UNIVERSITY SYSTEM

Inventor： BERGESON, Susan, E. ,  SYAPIN, Peter ,  REID, Ted, W.

IPC: A61K31/65 ,  C07C237/26

Abstract: The present invention includes novel molecules and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: identifying a subject in need of treatment for at least one of AUD, SUD, pain, or a proinflammatory disorder; and providing the subject with an effective amount of a modified minocycline to ameliorate or eliminate the AUD, SUD, pain, or proinflammatory disorder and that has reduced, or no, antimicrobial activity, wherein the modified tetracycline has a formula, e.g., or the modified doxycycline, minocycline, and tigecycline and their tautomerized structures, where the R-groups shown in the minocycline example above could be different combination of halogen, acetyl ester, methyl ester, and diacetal.